According to published data, the production and business results of the second quarter of 2022 of Cuu Long Pharmaceutical Joint Stock Company (DCL) is recorded its accounting profit before tax of VND 33 billion, equivalent to 196% compared to the first quarter of 2022, its profit after tax of VND 26 billion, equivalent to 193% compared to the previous quarter.
During the period, DCL’s net revenue was also recorded at VND 208.9 billion, an increase of VND 20 billion compared to the same period last year, gross profit was VND 64 billion, an increase of VND 6.3 billion compared to the same period last year.
For accumulated results of the first 6 months of the year, DCL’s net revenue recorded VND 426.3 billion, an increase of VND 60.2 billion compared to the same period last year, gross profit reached VND 118 billion, an increase of 15% compared to the same period last year. This is a positive signal for DCL to accelerate business results in the last 6 months of 2022.
Currently, for DCL’s cancer drug product, Benivatib with 100mg content and 400mg content, meeting European quality is winning major contracts of major hospitals such as National Institute Of Hematology & Blood Transfusion, Hanoi Oncology Hospital, Hospital 175, Blood Transfusion Hematology Hospital, Ho Chi Minh City, Nguyen Trai Hospital, Binh Dan Hospital, etc., the total winning value is nearly VND 200 billion. Since DCL participated in the bidding to supply this cancer drug to hospitals, it has helped patients reduce treatment costs and helped the state save the health insurance agency’s payment budget. DCL’s cancer drug patents also promise to bring in millions of dollars in sales for 2022 and beyond.
In addition, in the capsule production segment, DCL is also focusing on improving product quality to expand market share. DCL plans to invest in 4 more empty capsule production lines, increase capacity by 2 billion capsules/year and is expected to be put into operation in 2023.
